Table 4.
System | Injury stage | Criteria (serum creatinine) |
Criteria (urine output) |
---|---|---|---|
RIFLE | R (risk) |
≥1.5-fold Cr increase or GFR decrease ≥ 25 % |
<0.5 ml/kg/h for 6 h |
I (injury) |
≥2-fold Cr increase or GFR decrease ≥ 50 % |
<0.5 ml/kg/h for 12 h | |
F (failure) |
≥3-fold Cr increase or Cr >4.0 mg/dl |
<0.3 ml/kg/h or anuria for 12 h | |
L (loss) | Persistent failure >4 wk | ||
E (end stage) | Persistent failure >3 mo | ||
pRIFLE | R (risk) | GFR decrease ≥ 25 % | <0.5 ml/kg/h for 6 h |
I (injury) | GFR decrease ≥ 50 % | <0.5 ml/kg/h for 12 h | |
F (failure) |
GFR decrease ≥ 75 % or eGFR < 35 ml/min/1.73 m2 |
<0.3 ml/kg/h or anuria for 12 h | |
L (loss) | Persistent failure >4 wk | ||
E (end stage) | Persistent failure >3 mo | ||
AKIN | Stage 1 |
≥ 0.3 mg/dl Cr increase or 150–200 % increase above baseline |
<0.5 ml/kg/h for 6 h |
Stage 2 | Cr increase of 200–300 % of baseline | <0.5 ml/kg/h for 12 h | |
Stage 3 |
Cr increase ≥ 300 % of baseline or ≥4.0 mg/dl with an acute increase of 0.5 mg/dl |
<0.3 ml/kg/h or anuria for 12 h | |
KDIGO | Stage 1 |
≥ 0.3 mg/dl Cr increase or 1.5–1.9 times baseline |
<0.5 ml/kg/h for 6–12 h |
Stage 2 | Cr increase of 2.0–2.9 times baseline |
<0.5 ml/kg/h for ≥12 h |
|
Stage 3 |
Cr increase of 3.0 times baseline or Cr ≥4.0 mg/dl or initiation of renal replacement therapy or eGFR <35 ml/min per 1.73 m2 in patients <18 years |
<0.3 ml/kg/h for ≥24 h or anuria for ≥12 h |
AKIN, Acute Kidney Injury Network; KDIGO, Kidney Disease Improving Global Outcome; eGFR, estimated glomerular filtration rate